晚期肝细胞癌患者需要个体化管理:来自临床实践的教训
基于意大利肝癌数据库2008至2014年连续835例BCLC C期肝细胞癌患者,按临床特征分为PS1、PS2、MVI、EHS及MVI+EHS五亚组,中位总生存从PS1的38.6个月降至MVI+EHS的3.1个月(P<0.001),结论认为BCLC C期不够均质,需按PS和肿瘤特征细分并制定个体化治疗指征。
要点
- BCLC C期患者按PS、MVI、EHS亚分类后中位OS差异显著(P<0.001)。
- MVI患者中周围型MVI中位OS长于中央型(11.2 vs 7.1个月,P=0.005)。
- MVI+EHS患者最常用治疗为最佳支持治疗(51.7%)。
核心结论
- BCLC C期不足以将患者归为单一均质阶段,仅PS1不足以纳入该期,其余患者应按PS和肿瘤特征亚分类,需要新的个体化治疗指征。
研究设计与样本
- 基于意大利肝癌数据库分析2008至2014年诊断的835例连续BCLC C期肝细胞癌患者,按PS、MVI、EHS或MVI+EHS亚分类。
主要发现
- 亚组构成:PS1单独385例(46.1%)、PS2单独146例(17.5%)、MVI 224例(26.8%)、EHS 51例(6.1%)、MVI+EHS 29例(3.5%)。
- MVI、EHS及MVI+EHS患者较PS1和PS2患者肿瘤更大、多灶/巨块型更多且AFP水平更高。
- 中位OS从PS1的38.6个月依次降至PS2的22.3个月、EHS的11.2个月、MVI的8.2个月和MVI+EHS的3.1个月(P<0.001)。
- MVI患者中周围型MVI中位OS为11.2个月,长于中央型(门静脉主干)MVI的7.1个月(P=0.005)。
- 最常见治疗:PS1以根治性手段为主(39.7%),PS2以支持治疗为主(41.8%),MVI以索拉非尼为主(39.3%),EHS以索拉非尼为主(37.3%),MVI+EHS以最佳支持治疗为主(51.7%)。
临床怎么用
- 作者认为BCLC C期不应作为单一阶段管理,应按PS和肿瘤特征亚分类并制定个体化治疗指征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The Barcelona Clinic Liver Cancer (BCLC) advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study, our aim was to assess treatment and overall survival (OS) of BCLC C patients subclassified according to clinical features (performance status [PS], macrovascular invasion [MVI], extrahepatic spread [EHS] or MVI + EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analyzed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were subclassified as: PS1 alone (n = 385; 46.1%), PS2 alone (n = 146; 17.5%), MVI (n = 224; 26.8%), EHS (n = 51; 6.1%), and MVI + EHS (n = 29; 3.5%). MVI, EHS, and MVI + EHS patients had larger and multifocal/massive HCCs and higher alpha-fetoprotein (AFP) levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months), and MVI + EHS (3.1 months; P < 0.001). Among MVI patients, OS was longer in those with peripheral than with central (portal trunk) MVI (11.2 vs. 7.1 months; P = 0.005). The most frequent treatments were: curative approaches in PS1 (39.7%), supportive therapy in PS2 (41.8%), sorafenib in MVI (39.3%) and EHS (37.3%), and best supportive care in MVI + EHS patients (51.7%). Independent prognostic factors were: Model for End-stage Liver Disease score, Child-Pugh class, ascites, platelet count, albumin, tumor size, MVI, EHS, AFP levels, and treatment type. CONCLUSION: BCLC C stage does not identify patients homogeneous enough to be allocated to a single stage. PS1 alone is not sufficient to include a patient into this stage. The remaining patients should be subclassified according to PS and tumor features, and new patient-tailored therapeutic indications are needed. (Hepatology 2018;67:1784-1796).
引用
- Giannini EG, Bucci L, Garuti F, et al. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology. 2018. PMID: 29159910. doi:10.1002/hep.29668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。